This opinion piece aims to discuss some of these issues, including selection of patients for hereditary cancer genetic testing, exploring strategies for the identification of high-risk disease, and navigation of new treatment pathways for TNBC and hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer, with a specific focus on Canadian clinical practice. This evidence concerns the gene ERBB2 and cancer.